Sarcoidosis is a multisystem inflammatory disease that commonly affects the lungs, but its precise cause remains unknown. Although mortality is rare, sarcoidosis can cause significant morbidity, including debilitating fatigue and systemic upset, limiting the ability to work or carry out everyday activities. Mild cases may resolve spontaneously and never require treatment, but vital organ involvement is an indication for immunosuppression. The optimal choice of agent and duration of treatment remain unclear. Since sarcoidosis frequently presents to respiratory specialists, they need to be aware of the potential for extra-pulmonary disease and how to recognise it. Diagnosis and management of extra-pulmonary disease requires close collaboration between specialists in different disciplines.
KeywordsSarcoidosis Interstitial lung disease Granuloma Erythema nodosum Corticosteroids Immunosuppression Methotrexate
- 8.Cremers JP, Drent M, Bast A, Shigemitsu H, Baughman RP, Valeyre D, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013;19:545–61.CrossRefPubMedGoogle Scholar
- 15.Bone and Tooth Society, National Osteoporosis Society, Royal College of Physicians. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: RCP; 2002.Google Scholar
- 16.National Institute for Health and Care Excellence. Osteoporosis: assessing the risk of fragility fracture. NICE clinical guideline 146. 2012. Available at: www.nice.org.uk.
- 17.Statement on sarcoidosis. Joint statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736–55.Google Scholar